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The CAT assists prediction of COPD exacerbations 601COPD assessment
test;
PredictionCOPD outpatients with a history of exacerbation from 19 hospitals completed the CAT ques-
tionnaire and spirometry over six months. Exacerbation events were prospectively collected
using a structured questionnaire.
The baseline CAT score categorised into four groups (0e9, 10e19, 20e29, and 30e40) showed
strong prediction for time to first exacerbation and modest prediction for any exacerbation or
moderate-severe exacerbation (AUC 0.83, 0.64, and 0.63 respectively). In multivariate ana-
lyses, the categorised CAT score independently predicted all three outcomes (p Z 0.001 or
p< 0.001). Comparedwith the lowest CATscore category, the higher categories were associated
with significantly shorter time to first exacerbation and higher exacerbation risks. The corre-
sponding adjusted median time was >24, 14, 9, and 5 weeks and the adjusted RR was 1.00,
1.30, 1.37, and 1.50 in the category of 0e9, 10e19, 20e29, and 30e40 respectively. Exacerba-
tion history (2 vs. 1 event in the past year) was related to time to first exacerbation (adjusted
HR 1.35; pZ 0.023) and any exacerbation during the study period (adjusted RR 1.15; pZ 0.016).
The results of this study support the use of the CAT as a simple tool to assist in the identifica-
tion of patients at increased risk of exacerbations. This could facilitate timely and cost-
effective implementation of preventive interventions, and improve health resource allocation.
Trial registration: Clinicaltrials.gov: NCT01254032.
ª 2014 The Authors. Published by Elsevier Ltd.Open access under CC BY-NC-ND license.Introduction
Exacerbations of chronic obstructive pulmonary disease
(COPD) significantly impair health-related quality of life
(QoL), are associated with poor prognosis [1,2] and place a
huge economic burden on health services and society [3].
The Global initiative for chronic Obstructive Lung Disease
(GOLD) strategy document recommends use of a multidi-
mensional system based on post-bronchodilator forced
expiratory volume in 1 s (FEV1), exacerbation history and
symptom scores to stratify COPD patients into GOLD A, B, C
or D categories and guide the selection of pharmacological
therapy [4]. A recent study showed that there is substantial
heterogeneity in clinical characteristics among patients in
group D and the highest exacerbation rates were recorded
in this group [5]. This has led to the search for a tool to
assist stratification of patients who are at high risk of ex-
acerbations, particularly those placed in group D, according
to their imminence or likelihood of exacerbations. This may
facilitate initiation of prompt interventions and improve
planning and distribution of health resources.
Few studies have evaluated the potential of exacerba-
tion risk factors to stratify patients according to the
imminence or likelihood of exacerbation [6,7]. The spiro-
metric staging system defined by GOLD (GOLD stages 1e4)
[4] was found to lack the potential for risk stratification [7]
while the BMI/airflow obstruction/dyspnea/exercise ca-
pacity (BODE) index exhibits good prediction performance
but was not practical to be used in clinical practice [6].
Therefore, there is a need for a simple and reliable tool to
assist with the assessment of COPD exacerbation risk.
The recently developed CAT is a short self-administered
QoLquestionnaire [8]. It is readily available,easy tocomplete
and interpret, suitable for routine clinical use [9,10]. TheCAT
has demonstrated good correlation with established QoL
questionnaires and other relevant measures of disease
severity [8,11e13]. Further, it provides a good sense of the
health impact in COPD patients [14]. In an earlier study, the
CAT score was significantly different between stable and
exacerbated patients with COPD [8]. Moreover, longitudinalstudies showed that the CAT score relates to exacerbation
severity [15] and is responsive to changes in health status
during and after exacerbations [13,15,16].
We hypothesised that health status could be a premon-
itory sign of exacerbation and the CAT could be a useful tool
for predicting exacerbations. This study evaluates the
predictive value of the CAT for exacerbations and
moderate-severe exacerbations in the following six months,
and time to first exacerbation in COPD outpatients who are
at risk of exacerbations. It also examines the potential of
the CAT to further stratify these patients according to the
imminence or likelihood of exacerbations.Methods
Study design and population
In this prospective observational 6-month study, we
recruited 545 patients with COPD from outpatient clinics
across 19 hospitals in Australia, China, Korea and Taiwan
between August 2010 and April 2011. Patients were at least
40 years old, with smoking history of more than 10 pack-
years, established diagnosis of COPD for at least six months,
defined as FEV1/forced vital capacity (FVC) ratio <0.7 [4],
and with history of at least one COPD exacerbation, which
required additional treatment in the previous 12 months.
Patients with a current diagnosis of asthma were excluded.
All patients provided written informed consent and the
study was approved by the local ethics committees or re-
view boards prior to the initiation of any study-related
activities. The study was conducted in accordance with
Good Clinical Practice (GCP), all applicable patient privacy
requirements, and the ethical principles that are outlined
in the Declaration of Helsinki.
Study assessments
All patients attended the clinic every eight weeks and
received a telephone call every eight weeks in between
602 S.-D. Lee et al.study visits. Treatment history, COPD history, smoking his-
tory, and comorbidities were collected from the medical
records at the baseline visit. A structured clinical interview
was also conducted to record details of specific comorbid-
ities, including lung cancer, diabetes, peripheral artery
disease, rheumatoid disease, heart failure (any causes),
ischaemic heart disease (IHD), hypertension, and cardio-
vascular disease. At the baseline visit and each study visit,
health-related QoL, dyspnea, and lung function were
evaluated using the local language version of the CAT
questionnaire in each country, the Medical Research
Council (MRC) dyspnea scale, and spirometry respectively.
Spirometry was performed in accordance to the American
Thoracic Society/European Respiratory Society (ATS/ERS)
guidelines [17], and the predicted values were calculated
using reference equations appropriate for each country
[18e20]. GOLD stage was defined as post-bronchodilator
FEV1 % predicted values classified into 4 stages; stage 1:
80%, stage 2: 50e79%, stage 3: 30e49%, and stage 4:
<30% [4]. Exacerbations in the previous month were
assessed using a structured questionnaire at each study
visit and telephone contact. An exacerbation was defined
as worsening of symptoms of COPD for at least two
consecutive days and was classified as mild when patients
did not require treatment with systemic corticosteroids
and/or antibiotics; moderate when treatment with sys-
temic corticosteroids and/or antibiotics were required; or
severe when hospitalisation or visit to the emergency care
unit was required [21]. A separate exacerbation was
considered when an interval of clinical improvement of at
least 7 days was observed.Statistical analysis
Predictive models for the outcome of at least one COPD
exacerbation or moderate-severe exacerbation over the
following six months were developed. The predictive index
scores were obtained from two logistic regression models
and two cox regression models on time to first exacerba-
tion; based on baseline CAT score, uncategorised contin-
uous variable or categorised into four CAT score groups
(0e9, 10e19, 20e29, and 30e40). The predictive values of
the CAT score in subgroups; patients with any cardiovas-
cular comorbidity and patients with heart failure, IHD or
both, were also evaluated. The predictive value of changes
in CAT score over eight weeks (between two study visits) for
COPD exacerbation in subsequent study periods were also
evaluated.
Unadjusted and adjusted analyses were performed using
Poisson regression to evaluate the relationship between
baseline CAT scores and the occurrence of any exacerbation
or moderate-severe exacerbation. The analyses were
repeated using Cox regression to evaluate the relationship
between baseline CAT scores and time to first COPD exacer-
bation. Relevant clinical factors that could affect the out-
comes or baseline CAT scores were included in the adjusted
analyses: age, gender, body mass index (BMI), GOLD stages
(1e4), number of COPD exacerbations in the preceding year,
duration of COPD, current smoking status, number of
comorbidities, history of influenza vaccination, and country.
The median time to first COPD exacerbation by categorisedbaseline CAT score was estimated using the KaplaneMeier
technique. A p-value of less than 0.05 was considered sta-
tistically significant. All analyses were performed using SPSS
PASW Statistics 18 (SPSS Inc., Chicago, IL, USA).
Results
Patient characteristics
A total of 495 patients who had completed the CAT ques-
tionnaire at the baseline visit were included in the study
population. Table 1 shows the demographics and charac-
teristics at baseline for all patients and each baseline CAT
score category. The mean age was 69.4  8.8 years and 22%
were current smokers. The mean CAT score was 14.8  7.7
and 48% had a CAT score of 10e19. The median FEV1 was
47.0% (range 13.0e121.0%) of predicted normal value.
Nearly half of the patients (49%) had more than one COPD
exacerbation in the preceding year. There was a trend for
patients with higher baseline CAT scores to have longer
COPD duration, poorer lung function, and more frequent
exacerbations in the preceding year. Similarly, the preva-
lence of comorbidities and prior medication use tended to
be higher with higher CAT scores.
During the study period, 338 patients (68%) and 226 pa-
tients (46%) experienced at least one COPD exacerbation
and one moderate-severe exacerbation respectively
(Supplementary Table 1). There was a trend for increased
risk of exacerbations with higher baseline CAT scores (52%,
71%, 80%, and 100% for the four CAT score categories
in ascending order). A similar trend was observed
for the incidence of moderate-severe exacerbation (33%,
44%, 58%, and 95% respectively) (Supplementary Table 1).
The median exacerbation rate for the study population was
1.00 (range 0.00e6.00) episodes over six months.
Predictive ability of the CAT for COPD
exacerbations
The categorised CAT score showed a high predictive ability
for time to first exacerbation (area under the receiver
operating characteristic curve [AUC] 0.83) and a modest
predictive ability for any COPD exacerbation (AUC 0.64) or
moderate-severe exacerbation (AUC 0.63) in the following
six months (Table 2). The uncategorised CAT score provided
predictions of similar magnitude. In models adjusting for
potential confounders, the uncategorised CAT score
continued to show comparable prediction as the cat-
egorised CAT score. The sensitivity and specificity for pre-
diction of time to first exacerbation at the uncategorised
CAT score cut-off was 60% and 95% respectively. The
probability cut-off of the uncategorised CAT score to
observe a COPD exacerbation or moderate-severe exacer-
bation in a COPD patient was 11 and 17 respectively, with a
sensitivity and specificity of 75% and 47%, and 52% and 69%
respectively.
The categorised CAT score showed similar prediction
performance when tested in subgroups of patients with
cardiovascular comorbidity. The AUCs for time to first
exacerbation, exacerbation, and moderate-severe exacer-
bation were 0.87, 0.66, and 0.60 respectively in patients
Table 1 Demographics and other baseline characteristics
Characteristics Baseline CAT score category
0e9
(n Z 134)
10e19
(n Z 236)
20e29
(n Z 104)
30e40
(n Z 21)
All
(n Z 495)
Age (years) 69.0  8.5 69.7  8.9 69.4  9.1 69.9  7.9 69.4  8.8
Male 120 (90) 207 (88) 91 (88) 17 (81) 435 (88)
Asians 129 (96) 201 (85) 74 (71) 11 (52) 415 (84)
BMI (kg/m2) 23.7
(15.1e32.6)
23.1
(13.2e40.6)
22.0
(12.7e38.9)
21.1
(18.0e34.9)
23.0
(12.7e40.60)
COPD duration
(months)
27.0
(6.0e379.0)
32.5
(6.0e323.0)
56.5
(6.0e240.0)
72.0
(19.0e280.0)
36.0
(6.0e379.0)
Current smoker 36 (27) 47 (20) 20 (19) 4 (19) 107 (22)
Smoking history
(pack-years)
39.0
(10.0e150.0)
40.0
(10.0e138.0)
45.0
(11.0e175.0)
45.0
(19.0e196.0)
40.0
(10.0e196)
Post-bronchodilator
FEV1 (%predicted)
56.6
(19.4e101.0)
46.0
(13.0e99.0)
45.5
(14.0e121.0)
38.2
(14.5e92.0)
47.0
(13.0e121.0)
COPD exacerbation in
the preceding year
1 78 (58) 125 (53) 45 (43) 6 (29) 254 (51)
2 56 (42) 111 (47) 59 (57) 15 (71) 241 (49)
Comorbiditiesa
0 88 (66) 142 (60) 49 (47) 4 (19) 283 (57)
1e2 35 (26) 71 (30) 37 (36) 11 (52) 154 (31)
3 11 (8) 23 (10) 18 (17) 6 (29) 58 (12)
Cardiovascular
comorbiditiesb
39 (29) 85 (36) 49 (47) 16 (76) 189 (38)
CAT score 14.8  7.7
Medication history
Combination of
ICS and LABAc,d
62 (46) 150 (64) 78 (75) 19 (91) 309 (62)
LABAc,d 9 (7) 15 (6) 2 (2.0) 0 (0) 26 (5)
Long-acting
anticholinergicc,d
79 (59) 142 (60) 72 (69) 15 (71) 308 (62)
SABAc,d 41 (31) 108 (46) 59 (57) 12 (57) 220 (44)
Theophyllines
(long- and
short-acting)d
70 (52) 110 (47) 46 (44) 8 (38) 234 (47)
Systemic
corticosteroids
for COPD symptomse
38 (28) 85 (36) 47 (45) 16 (76) 186 (38)
Antibiotics for RTIe 59 (44) 130 (55) 71 (68) 16 (76) 276 (56)
Influenza
vaccinatione
43 (32) 92 (39) 56 (54) 13 (62) 204 (41)
Data are presented as mean  SD, n (%) or median (range).
BMI body mass index, CAT COPD assessment test, COPD chronic obstructive pulmonary disease, FEV1 forced expiratory volume in 1 s, ICS
inhaled corticosteroids, IHD ischaemic heart disease, LABA long-acting beta2-agonist, RTI respiratory tract infection, SABA short-acting
beta2-agonist.
a Includes lung cancer, diabetes, peripheral artery disease, rheumatoid disease, heart failure (any causes), IHD, or on anti-
hypertensive or other cardiovascular medication.
b Includes heart failure (any causes), IHD, or on anti-hypertensive or other cardiovascular medication.
c Inhalers.
d In the preceding 3 months.
e In the preceding 12 months.
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0.62 respectively in patients with heart failure, IHD or both
(Table 3).
Changes in CAT score between two study visits were
associated with low-modest prediction of exacerbations in
the subsequent study periods. Changes in CAT score at week8 from baseline showed relatively low predictive value for
exacerbations in the subsequent eight weeks (AUC 0.54;
95% CI 0.48e0.59) or 16 weeks (AUC 0.55; 95% CI
0.50e0.61). Changes in CAT score at week 16 from week 8
showed modest prediction (AUC 0.61; 95% CI 0.56e0.66) for
exacerbations in the subsequent eight weeks.
Table 2 Predictive value of baseline COPD assessment test (CAT) score and other risk factors for exacerbation
Prediction models AUC (95% CI)
Time to first
exacerbation
Any exacerbation Moderate-severe
exacerbation
Unadjusted Adjusteda Unadjusted Adjusteda Unadjusted Adjusteda
Categorised
CAT score
0.83
(0.79e0.87)
0.63
(0.57e0.68)
0.64
(0.59e0.70)
0.79
(0.75e0.84)
0.63
(0.58e0.68)
0.72
(0.68e0.77)
Uncategorised
CAT score
0.83
(0.79e0.87)
0.64
(0.59e0.69)
0.65
(0.59e0.70)
0.79
(0.75e0.83)
0.63
(0.58e0.68)
0.72
(0.67e0.77)
AUC area under the receiver operating characteristic (ROC) curve, BMI body mass index, CI confidence interval, COPD chronic
obstructive pulmonary disease.
a Adjusted for age, gender, BMI, duration of COPD, current smoking status, number of comorbidities, history of influenza vaccination,
and country. Categorised CAT score: baseline CAT score categorised into four groups (0e9, 10e19, 20e29, and 30e40).
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The results of multivariate analyses evaluating the rela-
tionship between the CAT score and time to first exacerba-
tion or risk of exacerbations are summarised in Table 4. In
unadjusted analysis, the categorised CAT score was signifi-
cantly associatedwith time tofirst exacerbation, and the risk
of having any COPD exacerbation or moderate-severe exac-
erbation (p < 0.001 for all). These relationships remained
significant even after adjusting for the effect of potential
confounders (p Z 0.001 or p < 0.001). Similarly, the unca-
tegorised CATscorewas also predictive of all three outcomes
in both unadjusted (p < 0.001 for all) and adjusted analyses
(p < 0.001, pZ 0.001; pZ 0.002 respectively) (Table 4).
The relationship between each CAT score category and
each outcome was evaluated. Higher CAT score categories
were associated with significantly shorter time to first
exacerbation, compared with the lowest category (Table 4).
The corresponding adjusted hazard ratios (HR) was 1.00,
1.73, 2.41, and 4.16 respectively (Table 4) and the adjusted
median timewas>24, 14, 9, and 5weeks respectively (Fig. 1)
for the four categories in ascending order. Similarly, higher
CAT score categories were associated with significantly
higher exacerbation risk; adjusted relative risks (RRs) 1.00,
1.30, 1.37, and 1.50 respectively (Table 4). Patients in the
highest category were at twice the risk of having moderate-Table 3 Predictive value of categorised COPD assessment test
AUC (95% CI)
Time to first exacerbation
(n Z 431)
Overall cohort 0.83 (0.79e0.87)
Any cardiovascular comorbiditya
Yes 0.87 (0.81e0.93)
No 0.82 (0.77e0.87)
Heart failure and/or IHD
Yes 0.82 (0.68e0.95)
No 0.83 (0.79e0.87)
Among patients with available data.
AUC area under the receiver operating characteristic (ROC) curve, CI
IHD ischaemic heart disease.
a Includes heart failure (any causes), IHD, or on anti-hypertensive osevere exacerbations (adjusted RR 2.01; p < 0.001) than
patients in the lowest category (Table 4).
Relationship between other factors and
exacerbations
Exacerbation history (2 vs. 1 event in the past year) was
significantly associated with time to first exacerbation
(pZ 0.023) and risk of any exacerbation (pZ 0.016) (Table
4). Compared with patients with less frequent prior exac-
erbations (1 event), those with frequent prior exacerba-
tions (2 events) showed a shorter time to first
exacerbation (adjusted HR 1.35) and increased risk of ex-
acerbations (adjusted RR 1.15). However, exacerbation
history was not associated with risk of moderate-severe
exacerbations; adjusted RR 1.14; p Z 0.181 (Table 4).
GOLD stage was significantly associated with time to first
exacerbation (p Z 0.029) and risk of moderate-severe ex-
acerbations (p Z 0.008), but not risk of any exacerbation
(p Z 0.128) (Table 4).
Discussion
This is the first large, multinational study assessing the pre-
dictive value of the CAT for COPD exacerbations in COPD(CAT) score for exacerbation among patient subgroups
Any exacerbation
(n Z 491)
Moderate-severe exacerbation
(n Z 490)
0.64 (0.59e0.70) 0.63 (0.58e0.68)
0.66 (0.56e0.76) 0.60 (0.53e0.69)
0.65 (0.59e0.72) 0.62 (0.55e0.68)
0.72 (0.58e0.86) 0.62 (0.48e0.76)
0.63 (0.58e0.69) 0.62 (0.57e0.68)
confidence interval, COPD chronic obstructive pulmonary disease,
r other cardiovascular medications.
Table 4 Relationship between baseline COPD assessment test (CAT) score and exacerbations
Factor Time to first exacerbation Any exacerbation Moderate-severe exacerbation
Hazard ratio
(95% CI)
p-Value Relative risk
(95% CI)
p-Value Relative risk
(95% CI)
p-Value
Uncategorised CAT scorea
(unadjusted)
1.06 (1.04e1.07) <0.001 1.02 (1.01e1.03) <0.001 1.03 (1.02e1.04) <0.001
Uncategorised CAT scorea,b
(adjusted)
1.05 (1.03e1.06) <0.001 1.01 (1.01e1.02) 0.001 1.02 (1.01e1.03) 0.002
Categorised CAT
score (unadjusted)
<0.001 <0.001 <0.001
0e9 1 1 1
10e19 1.72 (1.17e2.54) <0.001 1.35 (1.08e1.60) 0.004 1.31 (0.93e1.85) 0.174
20e29 2.64 (1.71e4.08) <0.001 1.53 (1.21e1.92) <0.001 1.73 (1.21e2.47) <0.001
30e40 6.14 (3.19e11.82) <0.001 1.91 (1.57e2.33) <0.001 2.86 (2.08e3.92) <0.001
Categorised CAT
score (adjusted)
0.001 <0.001 <0.001
0e9 1 1 1
10e19 1.73 (1.23e2.43) 0.001 1.30 (1.09e1.56) 0.004 1.18 (0.89e1.57) 0.251
20e29 2.41 (1.62e3.58) <0.001 1.37 (1.14e1.65) 0.001 1.40 (1.03e1.90) 0.330
30e40 4.16 (2.26e7.64) <0.001 1.50 (1.24e1.81) <0.001 2.01 (1.45e2.80) <0.001
Age (65 years vs. >65 years) 1.06 (0.79e1.42) 0.701 0.99 (0.87e1.13) 0.920 0.85 (0.67e1.06) 0.148
Gender (male vs. female) 0.86 (0.58e1.29) 0.469 1.01 (0.83e1.22) 0.958 1.17 (0.86e1.60) 0.319
BMI (21 kg/m2 vs. >21 kg/m2) 0.76 (0.57e1.02) 0.065 0.90 (0.79e1.03) 0.115 0.98 (0.80e1.20) 0.840
GOLD stagec 0.029 0.128 0.008
Stage 1 1 1 1
Stage 2 0.91 (0.57e1.44) 0.674 0.92 (0.75e1.12) 0.391 0.86 (0.60e1.23) 0.396
Stage 3 1.32 (0.83e2.09) 0.242 1.07 (0.89e1.30) 0.476 1.25 (0.89e1.76) 0.201
Stage 4 1.54 (0.89e2.68) 0.124 1.02 (0.81e1.27) 0.883 1.02 (0.68e1.54) 0.919
COPD exacerbations in the
preceding year (2 vs. 1)
1.35 (1.04e1.74) 0.023 1.15 (1.03e1.28) 0.016 1.14 (0.94e1.37) 0.181
Duration of COPD (months)a 1.00 (1.00e1.00) 0.684 1.00 (1.00e1.00) 0.445 1.00 (1.00e1.00) 0.506
Current smoking status
(yes vs. no)
1.37 (1.00e1.88) 0.052 1.04 (0.92e1.17) 0.577 0.97 (0.77e1.22) 0.787
Number of comorbiditiesd 0.854 0.417 0.076
1e2 vs. none 1.08 (0.81e1.45) 0.593 1.08 (0.96e1.21) 0.186 1.25 (1.01e1.54) 0.041
3 vs. none 1.02 (0.68e1.51) 0.941 1.05 (0.90e1.22) 0.543 1.29 (0.99e1.67) 0.058
Influenza vaccination
(yes vs. no)
1.33 (0.95e1.86) 0.098 1.07 (0.92e1.24) 0.376 1.47 (1.12e1.94) 0.005
Country e <0.001 e <0.001 e 0.295
Results presented are adjusted values unless otherwise stated.
BMI body mass index, COPD chronic obstructive pulmonary disease, CI confidence interval, GOLD global initiative for chronic obstructive
lung disease, IHD ischaemic heart disease.
a For continuous variables, the results are for per unit increase in variable.
b Full results of multivariate analyses of uncategorised CAT score are on file; covariables included in analyses are similar to those in
multivariate analyses of categorised CAT score as shown in the table.
c GOLD stage: post-bronchodilator FEV1 % predicted values classified into 4 stages (stage 1: 80%, stage 2: 50e79%, stage 3:30e49%,
and stage 4: <30%).
d Includes lung cancer, diabetes, peripheral artery disease, rheumatoid disease, heart failure (any causes), IHD, or on anti-
hypertensive or other cardiovascular medication.
The CAT assists prediction of COPD exacerbations 605outpatients who are at risk of exacerbations. Our study
provides important evidence on the potential of the CAT for
use as an additional tool to assist physicians to further
stratify patients who are at risk of exacerbations, based on
their exacerbation history, according to their imminence or
likelihood of exacerbations.
Our study showed that the CAT score, categorised into
four groups or used as a continuous variable, has a modest
predictive value for exacerbations and moderate-severe
exacerbations in the following six months (AUC 0.63e0.64).A similar level of predictive ability for COPD exacerbation
(AUC 0.62e0.69) was reported in other studies where the
prediction models consisted of a combination of risk fac-
tors, which may not be practical to use in clinical practice.
[7,22,23] These findings support the use of the CAT as a
convenient and reliable alternative to these models to
achieve the same level of prediction for exacerbations.
Our data suggest that the CAT score is consistent in its
predictive ability in different subgroups of patients.
Considering that heart disease is common among COPD
Figure 1 Adjusted time to first exacerbation by categorised baseline COPD assessment test (CAT) score. BMI body mass index,
COPD chronic obstructive pulmonary disease, GOLD global initiative for chronic obstructive lung disease. Time to first exacerbation
was adjusted for age, gender, BMI, GOLD stages (1e4), COPD exacerbation history in the preceding year, duration of COPD, current
smoking status, number of comorbidities, history of influenza vaccination, and country.
606 S.-D. Lee et al.patients and its symptoms may mimic those of COPD, we
assessed the performance of the CAT score in predicting
COPD exacerbations or time to first exacerbation in pa-
tients with cardiovascular comorbidity. We found pre-
dictions of similar magnitude as those observed with the
overall study population. This observation is encouraging
and suggests that the CAT score is reliable in predicting
exacerbations in the presence of cardiovascular comorbid-
ity. Further analysis on other patient subgroups is needed to
confirm this observation.
Several factors have been previously reported to be
associated with increased risk of exacerbation. These
include poorer health status [24e27], worsening lung
function [23,28], dyspnea [24], a history of exacerbation
[26], and more severe disease [26]. Hurst and colleagues
reported a history exacerbation (1 vs. 0 event) to be the
strongest predictor of exacerbations among other signifi-
cant factors [26]. Our findings extend previous findings and
show that frequent-exacerbation in the past year (2
events) is a strong predictor of exacerbations among pa-
tients who are at higher risk of exacerbations. Importantly,
we found that higher CAT scores remained associated with
increased exacerbation risks and shorter time to first
exacerbation after adjustment for relevant clinical factors.
The highest category was also associated with twice the risk
of moderate-severe exacerbations as the lowest category.
In contrast, we did not observe such trends with GOLD
stages. Taken together, these findings support the use of
exacerbation history to identify patients who at risk of
COPD exacerbation and the use of the CAT as a tool to
further stratify these patients who are at increased risk for
exacerbations according to the imminence and likelihood of
exacerbation, thereby facilitating timely and cost-effective
implementation of preventive interventions. Furthermore,
our findings also support the use of the CAT in the design ofclinical trials where COPD exacerbation is an outcome to
measure patients’ health status and facilitate more accu-
rate sample size calculation [29].
One of the strengths of this study is the large sample size,
which allowed a reasonable level of precision to be achieved
on the predictive power of the CAT for COPD exacerbation.
Using the CAT score, assessments of onset or risk of COPD
exacerbations can be performed easily and quickly as the
CAT questionnaire is conveniently applicable in clinics;
physicians need not collect a combination of other clinical
information to achieve the same level of prediction.
However, our findings need to be interpreted in light of a
few limitations. First, data on exacerbations were based on
patient’s recall, which may underestimate the exacerbation
rates. Nonetheless, the use of a structured questionnaire to
assess and classify exacerbations according to severity based
on the consensus definition by the ERS and the ATS, improved
the accuracy of patient recall and ensured consistency of
data collection, which reduced recall bias to some extent.
Furthermore, as the study was conducted over a 6-month
period, exacerbation rates may have been influenced by
seasonal variation, which could also impact upon the time to
first exacerbation. Future studies conducted over a period of
at least one year could overcome seasonal variations in ex-
acerbations and provide more robust results. Our study
recruited a specific population of COPD patients with prior
exacerbations in the preceding year. Therefore, our pre-
diction model may not be generally applicable to all patients
with COPD, specifically those with a lower rate of exacer-
bations. Finally, the relatively short study duration only
allowed small changes in patients’ CAT score to be captured.
Hence, only a preliminary evaluation of the predictive value
of changes in CAT score for subsequent exacerbations can be
made in this study. A study of a longer duration will provide
further information.
The CAT assists prediction of COPD exacerbations 607Conclusions
In patients with a history of exacerbations in the preceding
year, the CAT can identify patients at further risk of exac-
erbations in the following six months. This may allow better
informed decisions in the clinical management of COPD
patients and improve health resource allocation. The CAT
may also be used in the design of clinical trials targeting
COPD population at high risk of exacerbations.
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